AI-generated research brief — verify at source
Fixed Two-Year Lenalidomide Maintenance Matches Indefinite Therapy in Overall Survival
In a phase 3 randomised trial of 516 patients with standard-risk newly diagnosed multiple myeloma, indefinite-duration lenalidomide maintenance produced virtually identical seven-year overall survival compared with a fixed two-year course — 68.6% versus 69.0%, a difference of just −0.4 percentage points (95% CI −9.0 to 8.3; P = 0.93). The result challenges the prevailing practice of continuing lenalidomide indefinitely, while also revealing a meaningfully higher burden of toxicity and second primary cancers with continuous therapy.
What Was Studied
The trial investigated whether indefinite lenalidomide maintenance — the current standard approach — offers a survival advantage over a time-limited two-year course in patients with standard-risk multiple myeloma who did not receive an upfront autologous stem-cell transplant. The primary endpoint was overall survival, with the study designed to detect a clinically meaningful prolongation of median survival from five to seven and a half years.
How It Was Studied
This was a phase 3 randomised controlled trial conducted under the ENDURANCE platform (NCT01863550), funded by the National Cancer Institute and Amgen. Eligible patients had standard-risk newly diagnosed multiple myeloma and did not undergo upfront autologous stem-cell transplantation. All participants first completed induction therapy with a proteasome inhibitor combined with lenalidomide, after which 516 patients were randomly assigned — 260 to continuous lenalidomide until disease progression and 256 to a fixed two-year lenalidomide course. Median follow-up reached 86 months, providing a lengthy observational window suited to detecting late divergence in survival outcomes.
What Was Observed
- Overall survival was statistically indistinguishable between arms. Seven-year OS was 68.6% in the indefinite-duration group and 69.0% in the fixed-duration group — a negligible difference of −0.4 percentage points (95% CI −9.0 to 8.3; P = 0.93), with 80 deaths recorded in each group. This provides no evidence that continuing lenalidomide beyond two years prolongs life in this population.
- Progression-free survival favoured indefinite therapy numerically but not conclusively. Seven-year PFS was 36.1% with continuous lenalidomide versus 29.7% with fixed-duration therapy — a difference of 6.4 percentage points (95% CI −2.6 to 15.4). The confidence interval crosses zero, meaning this difference is not statistically significant, though the direction consistently favoured longer treatment.
- Second primary cancers occurred more frequently with indefinite lenalidomide. The five-year cumulative incidence of second primary cancers (excluding nonmelanoma skin cancer) was 11.2% in the continuous arm compared with 8.3% in the fixed-duration arm — a clinically notable difference given the absence of any accompanying survival benefit with the longer regimen.
- Toxicity was substantially higher with continuous therapy. Grade 3 or higher nonhematologic adverse events occurred in 48.2% of patients receiving indefinite lenalidomide, compared with 31.5% in the two-year group — representing a roughly 17 percentage-point excess in serious non-blood toxicity that accumulated over the extended treatment period.
Why This Matters
The trial directly challenges the assumption that indefinite lenalidomide maintenance is necessary for optimal outcomes in standard-risk multiple myeloma managed without upfront transplant. Despite a modest numerical advantage in progression-free survival with continuous therapy, this did not translate into any detectable improvement in overall survival, while patients in the indefinite arm experienced substantially more serious adverse events and a higher incidence of second primary malignancies. These findings raise the possibility that a fixed, time-limited maintenance strategy may achieve comparable long-term survival while meaningfully reducing cumulative treatment burden.
How to Read This Result
While the trial design is robust and follow-up is long, the study accrued only 160 deaths against a prespecified target of 204, leaving it modestly underpowered to exclude a survival difference with full confidence — meaning a small true benefit of indefinite therapy cannot be entirely ruled out on current data.
Limitations
The most important methodological constraint is that the trial did not reach its planned event count: 160 deaths were observed versus the 204 required to achieve 80% power to detect a 50% increase in median overall survival, which reduces the reliability of a null conclusion. Additionally, the trial enrolled only patients with standard-risk disease who did not receive upfront autologous stem-cell transplantation, so the findings cannot be extended to higher-risk patients or to transplant-eligible populations who may respond differently to duration of maintenance therapy.